Virtual Clinical Trials, an Essential Step in Increasing the Effectiveness of the Drug Development Process

Public Health Genomics

Volumn 18, Issue 6, 2015, Pages 366-371

  Lehrach, Hans ^a  

^a ALACRIS THERANOSTICS GMBH   (Germany)

Author keywords

Drug development; Drug discovery; In silico clinical trials; Mechanistic models; Personalised medicine; Predictive modelling; Virtual patient

Indexed keywords

DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; COMPUTER SIMULATION; DNA SEQUENCE; DRUG DEVELOPMENT; HUMAN; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; TRANSCRIPTOMICS; VIRTUAL REALITY; COMPUTER INTERFACE; FEMALE; MALE; PROCEDURES;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DRUG DISCOVERY; FEMALE; HUMANS; MALE; PRECISION MEDICINE; USER-COMPUTER INTERFACE;

EID: 84952870358     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000441553     Document Type: Article

References (24)

1. Stewart BW, Wild CP: World Cancer Report 2014. Geneva, World Health Organization, 2004.
2. Luengo-Fernandez R, Leal J, Gray A, Sullivan R: Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013; 14: 1165-1174.
3. European Commission: Population groups: elderly. http://ec.europa.eu/health/population- groups/elderly/index-en.htm.
4. Busse R, Blümel M, Scheller-Kreinsen D, Zentner A: Tackling chronic diseases in Europe: strategies, interventions and challenges. Observatory Studies Series No 20. Geneva, World Health Organization, 2010.
5. Spear ABB, Heath-Chiozzi M, Huff J: Clinical application of pharmacogenetics. Trends Mol Med 2001; 7: 201-204.
6. Einsidel EF: Emerging Technologies: From Hindsight to Foresight. Toronto, UBC, 2009, p 360.
7. Poste G: Bring on the biomarkers. Nature 2011; 469: 156-157.
8. Wierling C, Herwig R, Lehrach H: Resources, standards and tools for systems biology. Brief Funct Genomic Proteomic 2007; 6: 240-251.
9. Wierling C, Kühn A, Hache H, Daskalaki A, Maschke-Dutz E, Peycheva S, Li J, Herwig R, Lehrach H: Prediction in the face of uncertainty: a Monte Carlo-based approach for systems biology of cancer treatment. Mutat Res 2012; 746: 163-170.
10. Röhr C, Kerick M, Fischer A, Kühn A, Kashofer K, Timmermann B, Daskalaki A, Meinel T, Drichel D, Börno ST, Nowka A, Krobitsch S, McHardy AC, Kratsch C, Becker T, Wunderlich A, Barmeyer C, Viertler C, Zat loukal K, Wierling C, Lehrach H, Schweiger MR: High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. PLoS One 2013; 8:e67461.
11. Henderson D, Ogilvie LA, Hoyle N, Keilholz U, Lange B, Lehrach H: Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. Biotechnol J 2014; 9: 1104-1114.
12. Prometeus GmbH: TOP500. http://www.top500.org/statistics/perfdevel/.
13. Haby J: Forecast model data input. http://www.theweatherprediction.com/habyhints/60/.
14. Glökler J, Warnatz HJ: CDR sequence-specific enrichment of live immune cells. European Patent Application 2012 No 12165009.7.
15. Lee JH, Daugharthy ER, Scheiman J, Kalhor R, Yang JL, Ferrante TC, Terry R, Jeanty SS, Li C, Amamoto R, Peters DT, Turczyk BM, Marblestone AH, Inverso SA, Bernard A, Mali P, Rios X, Aach J, Church GM: Highly multiplexed subcellular RNA sequencing in situ. Science 2014; 343: 1360-1363.
16. Lee J, Daugharthy ER, Scheiman J, Kalhor R, Ferrente TC, Terry R, Turczyk B, Yang JL, Lee HS, Aach J, Zhang K, Church GM: Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues. Nat Protoc 2015; 10: 442-458.
17. Gu GJ, Friedman M, Jost C, Johnsson K, Kamali-Moghaddam M, Plückthun A, Landegren U, Söderberg O: Protein tag-mediated conjugation of oligonucleotides to recombinant affinity binders for proximity ligation. N Biotechnol 2013; 30: 144-152.
18. Weibrecht I, Gavrilovic M, Lindbom L, Landegren U, Wählby C, Söderberg O: Visualising individual sequence-specific protein-DNA interactions in situ. N Biotechnol 2012; 29: 589-598.
19. Eurofound: Absence from work. 2010. http://www.eurofound.europa.eu/observatories/eurwork/comparative-information/absencefrom-work.
20. Tufts Center for the Study of Drug Development: Cost to develop and win marketing approval for a new drug is 2.6 billion. 2014. http://csdd.tufts.edu/news/complete-story/pr-tufts-csdd-2014-cost-study.
21. International Cancer Genome Consortium: International network of cancer genome projects. Nature 2010; 464: 993-998.
22. Hood L, Balling R, Auffray C: Revolutionizing medicine in the 21st century through systems approaches. Biotechnol J 2012; 7: 992-1001.
23. European Commission: Regulation of the European Parliament and of the Council on the protection of individuals with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation).
24. OECD: Fiscal Sustainability of Health Care Systems: Bridging Health and Finance Perspectives. Paris, OECD, 2015.